dimenhydrinate (Rx, OTC)

Brand and Other Names:Dramamine
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

injectable solution

  • 50mg/mL

tablet

  • 50mg

tablet, chewable

  • 50mg

Prevention of Motion Sickness

50-100 mg PO/IV/IM q4-6hr PRN, 30 minutes before exposure to motion; not to exceed 400 mg/day

Meniere's Disease (Off-label)

25-50 mg PO q8hr for maintenance

50 mg IM for acute attack

Administration

IV: 50 mg in 10 mL NS over 2 minutes

Dosage Forms & Strengths

injectable solution

  • 50mg/mL

tablet, chewable

  • 50mg

tablet

  • 50mg

Prevention of Motion Sickness

General dose: 1.25 mg/kg or 37.5 mg/sq.meter IV/IM q6hr; not exceed 300 mg/day  

2-6 years old: 12.5-25 mg PO q6-8hr; no more than 75 mg/day

6-12 years old: 12.5-25 mg PO q6-8hr; no more than 150 mg/day

>12 years old: Same as adult dosing

Prevention of Motion Sickness

50-100 mg PO/IV/IM q4-6hr PRN, 30 minutes before exposure to motion; not to exceed 400 mg/day

Meniere's Disease (Off-label)

25-50 mg PO q8hr for maintenance, 50 mg IM for acute attack

Next:

Interactions

Interaction Checker

and dimenhydrinate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (6)

              • calcium/magnesium/potassium/sodium oxybates

                dimenhydrinate, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • eluxadoline

                dimenhydrinate, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.

              • metoclopramide intranasal

                dimenhydrinate, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

              • pitolisant

                dimenhydrinate decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.

              • secretin

                dimenhydrinate decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.

              • sodium oxybate

                dimenhydrinate, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              Monitor Closely (196)

              • albuterol

                dimenhydrinate increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • alfentanil

                dimenhydrinate and alfentanil both increase sedation. Use Caution/Monitor.

              • alprazolam

                dimenhydrinate and alprazolam both increase sedation. Use Caution/Monitor.

              • amitriptyline

                dimenhydrinate and amitriptyline both increase sedation. Use Caution/Monitor.

              • amobarbital

                dimenhydrinate and amobarbital both increase sedation. Use Caution/Monitor.

              • amoxapine

                dimenhydrinate and amoxapine both increase sedation. Use Caution/Monitor.

              • apomorphine

                dimenhydrinate and apomorphine both increase sedation. Use Caution/Monitor.

              • arformoterol

                dimenhydrinate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • aripiprazole

                dimenhydrinate and aripiprazole both increase sedation. Use Caution/Monitor.

              • armodafinil

                dimenhydrinate increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • azelastine

                azelastine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • baclofen

                dimenhydrinate and baclofen both increase sedation. Use Caution/Monitor.

              • belladonna and opium

                dimenhydrinate and belladonna and opium both increase sedation. Use Caution/Monitor.

              • benperidol

                dimenhydrinate and benperidol both increase sedation. Use Caution/Monitor.

              • benzphetamine

                dimenhydrinate increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • benztropine

                dimenhydrinate increases toxicity of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects.

              • brexanolone

                brexanolone, dimenhydrinate. Either increases toxicity of the other by sedation. Use Caution/Monitor.

              • brompheniramine

                brompheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • buprenorphine

                dimenhydrinate and buprenorphine both increase sedation. Use Caution/Monitor.

              • buprenorphine buccal

                dimenhydrinate and buprenorphine buccal both increase sedation. Use Caution/Monitor.

              • butabarbital

                dimenhydrinate and butabarbital both increase sedation. Use Caution/Monitor.

              • butalbital

                dimenhydrinate and butalbital both increase sedation. Use Caution/Monitor.

              • butorphanol

                dimenhydrinate and butorphanol both increase sedation. Use Caution/Monitor.

              • caffeine

                dimenhydrinate increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • carbinoxamine

                carbinoxamine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • carisoprodol

                dimenhydrinate and carisoprodol both increase sedation. Use Caution/Monitor.

              • chloral hydrate

                dimenhydrinate and chloral hydrate both increase sedation. Use Caution/Monitor.

              • chlordiazepoxide

                dimenhydrinate and chlordiazepoxide both increase sedation. Use Caution/Monitor.

              • chlorpheniramine

                chlorpheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • chlorpromazine

                dimenhydrinate and chlorpromazine both increase sedation. Use Caution/Monitor.

              • chlorzoxazone

                dimenhydrinate and chlorzoxazone both increase sedation. Use Caution/Monitor.

              • cinnarizine

                cinnarizine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • clemastine

                clemastine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • clobazam

                dimenhydrinate, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

              • clomipramine

                dimenhydrinate and clomipramine both increase sedation. Use Caution/Monitor.

              • clonazepam

                dimenhydrinate and clonazepam both increase sedation. Use Caution/Monitor.

              • clorazepate

                dimenhydrinate and clorazepate both increase sedation. Use Caution/Monitor.

              • clozapine

                dimenhydrinate and clozapine both increase sedation. Use Caution/Monitor.

              • codeine

                dimenhydrinate and codeine both increase sedation. Use Caution/Monitor.

              • cyclizine

                cyclizine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • cyclobenzaprine

                dimenhydrinate and cyclobenzaprine both increase sedation. Use Caution/Monitor.

              • cyproheptadine

                cyproheptadine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • dantrolene

                dimenhydrinate and dantrolene both increase sedation. Use Caution/Monitor.

              • desflurane

                desflurane and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • desipramine

                dimenhydrinate and desipramine both increase sedation. Use Caution/Monitor.

              • deutetrabenazine

                dimenhydrinate and deutetrabenazine both increase sedation. Use Caution/Monitor.

              • dexchlorpheniramine

                dexchlorpheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • dexfenfluramine

                dimenhydrinate increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexmedetomidine

                dimenhydrinate and dexmedetomidine both increase sedation. Use Caution/Monitor.

              • dexmethylphenidate

                dimenhydrinate increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dextroamphetamine

                dimenhydrinate increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dextromoramide

                dimenhydrinate and dextromoramide both increase sedation. Use Caution/Monitor.

              • diamorphine

                dimenhydrinate and diamorphine both increase sedation. Use Caution/Monitor.

              • diazepam

                dimenhydrinate and diazepam both increase sedation. Use Caution/Monitor.

              • diazepam intranasal

                diazepam intranasal, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.

              • diethylpropion

                dimenhydrinate increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • difenoxin hcl

                dimenhydrinate and difenoxin hcl both increase sedation. Use Caution/Monitor.

              • diphenhydramine

                dimenhydrinate and diphenhydramine both increase sedation. Use Caution/Monitor.

              • diphenoxylate hcl

                dimenhydrinate and diphenoxylate hcl both increase sedation. Use Caution/Monitor.

              • dipipanone

                dimenhydrinate and dipipanone both increase sedation. Use Caution/Monitor.

              • dobutamine

                dimenhydrinate increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dopamine

                dimenhydrinate increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dopexamine

                dimenhydrinate increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dosulepin

                dimenhydrinate and dosulepin both increase sedation. Use Caution/Monitor.

              • doxepin

                dimenhydrinate and doxepin both increase sedation. Use Caution/Monitor.

              • doxylamine

                dimenhydrinate and doxylamine both increase sedation. Use Caution/Monitor.

              • droperidol

                dimenhydrinate and droperidol both increase sedation. Use Caution/Monitor.

              • ephedrine

                dimenhydrinate increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • epinephrine

                dimenhydrinate increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • epinephrine racemic

                dimenhydrinate increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • esketamine intranasal

                esketamine intranasal, dimenhydrinate. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

              • estazolam

                dimenhydrinate and estazolam both increase sedation. Use Caution/Monitor.

              • ethanol

                dimenhydrinate and ethanol both increase sedation. Use Caution/Monitor.

              • etomidate

                etomidate and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • fenfluramine

                dimenhydrinate increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fentanyl

                fentanyl, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl intranasal

                fentanyl intranasal, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transdermal

                fentanyl transdermal, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transmucosal

                fentanyl transmucosal, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • flibanserin

                dimenhydrinate and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.

              • fluphenazine

                dimenhydrinate and fluphenazine both increase sedation. Use Caution/Monitor.

              • flurazepam

                dimenhydrinate and flurazepam both increase sedation. Use Caution/Monitor.

              • formoterol

                dimenhydrinate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • gabapentin

                gabapentin, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • gabapentin enacarbil

                gabapentin enacarbil, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • glycopyrronium tosylate topical

                glycopyrronium tosylate topical, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

              • gotu kola

                gotu kola increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • haloperidol

                dimenhydrinate and haloperidol both increase sedation. Use Caution/Monitor.

              • hawthorn

                hawthorn increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • hops

                hops increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • hyaluronidase

                dimenhydrinate decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.

              • hydromorphone

                dimenhydrinate and hydromorphone both increase sedation. Use Caution/Monitor.

              • hydroxyzine

                dimenhydrinate and hydroxyzine both increase sedation. Use Caution/Monitor.

              • iloperidone

                dimenhydrinate and iloperidone both increase sedation. Use Caution/Monitor.

              • imipramine

                dimenhydrinate and imipramine both increase sedation. Use Caution/Monitor.

              • incobotulinumtoxinA

                dimenhydrinate, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.

              • isoproterenol

                dimenhydrinate increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • kava

                kava increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • ketamine

                ketamine and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • ketotifen, ophthalmic

                dimenhydrinate and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

              • lasmiditan

                lasmiditan, dimenhydrinate. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

              • lemborexant

                lemborexant, dimenhydrinate. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

              • levalbuterol

                dimenhydrinate increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • levorphanol

                dimenhydrinate and levorphanol both increase sedation. Use Caution/Monitor.

              • lisdexamfetamine

                dimenhydrinate increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lofepramine

                dimenhydrinate and lofepramine both increase sedation. Use Caution/Monitor.

              • lofexidine

                dimenhydrinate and lofexidine both increase sedation. Use Caution/Monitor.

              • loprazolam

                dimenhydrinate and loprazolam both increase sedation. Use Caution/Monitor.

              • lorazepam

                dimenhydrinate and lorazepam both increase sedation. Use Caution/Monitor.

              • lormetazepam

                dimenhydrinate and lormetazepam both increase sedation. Use Caution/Monitor.

              • loxapine

                dimenhydrinate and loxapine both increase sedation. Use Caution/Monitor.

              • loxapine inhaled

                dimenhydrinate and loxapine inhaled both increase sedation. Use Caution/Monitor.

              • lurasidone

                lurasidone, dimenhydrinate. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

              • maprotiline

                dimenhydrinate and maprotiline both increase sedation. Use Caution/Monitor.

              • marijuana

                dimenhydrinate and marijuana both increase sedation. Use Caution/Monitor.

              • melatonin

                dimenhydrinate and melatonin both increase sedation. Use Caution/Monitor.

              • meperidine

                dimenhydrinate and meperidine both increase sedation. Use Caution/Monitor.

              • meprobamate

                dimenhydrinate and meprobamate both increase sedation. Use Caution/Monitor.

              • metaproterenol

                dimenhydrinate increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • metaxalone

                dimenhydrinate and metaxalone both increase sedation. Use Caution/Monitor.

              • methadone

                dimenhydrinate and methadone both increase sedation. Use Caution/Monitor.

              • methamphetamine

                dimenhydrinate increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • methocarbamol

                dimenhydrinate and methocarbamol both increase sedation. Use Caution/Monitor.

              • methylenedioxymethamphetamine

                dimenhydrinate increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • midazolam

                dimenhydrinate and midazolam both increase sedation. Use Caution/Monitor.

              • midazolam intranasal

                midazolam intranasal, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

              • midodrine

                dimenhydrinate increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • mirtazapine

                dimenhydrinate and mirtazapine both increase sedation. Use Caution/Monitor.

              • modafinil

                dimenhydrinate increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • morphine

                dimenhydrinate and morphine both increase sedation. Use Caution/Monitor.

              • motherwort

                dimenhydrinate and motherwort both increase sedation. Use Caution/Monitor.

              • moxonidine

                dimenhydrinate and moxonidine both increase sedation. Use Caution/Monitor.

              • nabilone

                dimenhydrinate and nabilone both increase sedation. Use Caution/Monitor.

              • nalbuphine

                dimenhydrinate and nalbuphine both increase sedation. Use Caution/Monitor.

              • norepinephrine

                dimenhydrinate increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nortriptyline

                dimenhydrinate and nortriptyline both increase sedation. Use Caution/Monitor.

              • olanzapine

                dimenhydrinate and olanzapine both increase sedation. Use Caution/Monitor.

              • opium tincture

                dimenhydrinate and opium tincture both increase sedation. Use Caution/Monitor.

              • orphenadrine

                dimenhydrinate and orphenadrine both increase sedation. Use Caution/Monitor.

              • oxazepam

                dimenhydrinate and oxazepam both increase sedation. Use Caution/Monitor.

              • oxycodone

                dimenhydrinate and oxycodone both increase sedation. Use Caution/Monitor.

              • oxymorphone

                dimenhydrinate and oxymorphone both increase sedation. Use Caution/Monitor.

              • paliperidone

                dimenhydrinate and paliperidone both increase sedation. Use Caution/Monitor.

              • papaveretum

                dimenhydrinate and papaveretum both increase sedation. Use Caution/Monitor.

              • papaverine

                dimenhydrinate and papaverine both increase sedation. Use Caution/Monitor.

              • passion flower

                passion flower increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • pentazocine

                dimenhydrinate and pentazocine both increase sedation. Use Caution/Monitor.

              • pentobarbital

                dimenhydrinate and pentobarbital both increase sedation. Use Caution/Monitor.

              • perphenazine

                dimenhydrinate and perphenazine both increase sedation. Use Caution/Monitor.

              • phendimetrazine

                dimenhydrinate increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenobarbital

                dimenhydrinate and phenobarbital both increase sedation. Use Caution/Monitor.

              • phentermine

                dimenhydrinate increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenylephrine

                dimenhydrinate increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenylephrine PO

                dimenhydrinate increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • pholcodine

                dimenhydrinate and pholcodine both increase sedation. Use Caution/Monitor.

              • pimozide

                dimenhydrinate and pimozide both increase sedation. Use Caution/Monitor.

              • pirbuterol

                dimenhydrinate increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pregabalin

                pregabalin, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • primidone

                dimenhydrinate and primidone both increase sedation. Use Caution/Monitor.

              • prochlorperazine

                dimenhydrinate and prochlorperazine both increase sedation. Use Caution/Monitor.

              • promethazine

                dimenhydrinate and promethazine both increase sedation. Use Caution/Monitor.

              • propofol

                propofol and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • propylhexedrine

                dimenhydrinate increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • protriptyline

                dimenhydrinate and protriptyline both increase sedation. Use Caution/Monitor.

              • quazepam

                dimenhydrinate and quazepam both increase sedation. Use Caution/Monitor.

              • quetiapine

                dimenhydrinate and quetiapine both increase sedation. Use Caution/Monitor.

              • ramelteon

                dimenhydrinate and ramelteon both increase sedation. Use Caution/Monitor.

              • rimabotulinumtoxinB

                dimenhydrinate, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.

              • risperidone

                dimenhydrinate and risperidone both increase sedation. Use Caution/Monitor.

              • salmeterol

                dimenhydrinate increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • scullcap

                dimenhydrinate and scullcap both increase sedation. Use Caution/Monitor.

              • secobarbital

                dimenhydrinate and secobarbital both increase sedation. Use Caution/Monitor.

              • sevoflurane

                sevoflurane and dimenhydrinate both increase sedation. Use Caution/Monitor.

              • shepherd's purse

                dimenhydrinate and shepherd's purse both increase sedation. Use Caution/Monitor.

              • stiripentol

                stiripentol, dimenhydrinate. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

              • sufentanil

                dimenhydrinate and sufentanil both increase sedation. Use Caution/Monitor.

              • tapentadol

                dimenhydrinate and tapentadol both increase sedation. Use Caution/Monitor.

              • temazepam

                dimenhydrinate and temazepam both increase sedation. Use Caution/Monitor.

              • terbutaline

                dimenhydrinate increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • thioridazine

                dimenhydrinate and thioridazine both increase sedation. Use Caution/Monitor.

              • thiothixene

                dimenhydrinate and thiothixene both increase sedation. Use Caution/Monitor.

              • topiramate

                dimenhydrinate and topiramate both increase sedation. Modify Therapy/Monitor Closely.

              • tramadol

                dimenhydrinate and tramadol both increase sedation. Use Caution/Monitor.

              • trazodone

                dimenhydrinate and trazodone both increase sedation. Use Caution/Monitor.

              • triazolam

                dimenhydrinate and triazolam both increase sedation. Use Caution/Monitor.

              • triclofos

                dimenhydrinate and triclofos both increase sedation. Use Caution/Monitor.

              • trifluoperazine

                dimenhydrinate and trifluoperazine both increase sedation. Use Caution/Monitor.

              • trihexyphenidyl

                dimenhydrinate increases toxicity of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects.

              • trimipramine

                dimenhydrinate and trimipramine both increase sedation. Use Caution/Monitor.

              • triprolidine

                dimenhydrinate and triprolidine both increase sedation. Use Caution/Monitor.

              • valerian

                valerian increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • xylometazoline

                dimenhydrinate increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • yohimbine

                dimenhydrinate increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ziconotide

                dimenhydrinate and ziconotide both increase sedation. Use Caution/Monitor.

              • ziprasidone

                dimenhydrinate and ziprasidone both increase sedation. Use Caution/Monitor.

              • zotepine

                dimenhydrinate and zotepine both increase sedation. Use Caution/Monitor.

              Minor (46)

              • aclidinium

                dimenhydrinate increases toxicity of aclidinium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • anticholinergic/sedative combos

                dimenhydrinate increases toxicity of anticholinergic/sedative combos by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • ashwagandha

                ashwagandha increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

              • atracurium

                dimenhydrinate increases toxicity of atracurium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • atropine

                dimenhydrinate increases toxicity of atropine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • atropine IV/IM

                dimenhydrinate increases toxicity of atropine IV/IM by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • belladonna alkaloids

                dimenhydrinate increases toxicity of belladonna alkaloids by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • belladonna and opium

                dimenhydrinate increases toxicity of belladonna and opium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • brimonidine

                brimonidine increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • cisatracurium

                dimenhydrinate increases toxicity of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • cyclizine

                dimenhydrinate increases toxicity of cyclizine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • cyclobenzaprine

                dimenhydrinate increases toxicity of cyclobenzaprine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • darifenacin

                dimenhydrinate increases toxicity of darifenacin by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • dicyclomine

                dimenhydrinate increases toxicity of dicyclomine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • diphenhydramine

                dimenhydrinate increases toxicity of diphenhydramine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • eucalyptus

                dimenhydrinate and eucalyptus both increase sedation. Minor/Significance Unknown.

              • fesoterodine

                dimenhydrinate increases toxicity of fesoterodine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • flavoxate

                dimenhydrinate increases toxicity of flavoxate by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • glycopyrrolate

                dimenhydrinate increases toxicity of glycopyrrolate by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • glycopyrrolate inhaled

                dimenhydrinate increases toxicity of glycopyrrolate inhaled by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • henbane

                dimenhydrinate increases toxicity of henbane by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • homatropine

                dimenhydrinate increases toxicity of homatropine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • hyoscyamine

                dimenhydrinate increases toxicity of hyoscyamine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • hyoscyamine spray

                dimenhydrinate increases toxicity of hyoscyamine spray by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • ipratropium

                dimenhydrinate increases toxicity of ipratropium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • meclizine

                dimenhydrinate increases toxicity of meclizine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • methscopolamine

                dimenhydrinate increases toxicity of methscopolamine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • nettle

                nettle increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.

              • onabotulinumtoxinA

                dimenhydrinate increases toxicity of onabotulinumtoxinA by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • oxybutynin

                dimenhydrinate increases toxicity of oxybutynin by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • oxybutynin topical

                dimenhydrinate increases toxicity of oxybutynin topical by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • oxybutynin transdermal

                dimenhydrinate increases toxicity of oxybutynin transdermal by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • pancuronium

                dimenhydrinate increases toxicity of pancuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • pralidoxime

                dimenhydrinate increases toxicity of pralidoxime by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • propantheline

                dimenhydrinate increases toxicity of propantheline by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • rapacuronium

                dimenhydrinate increases toxicity of rapacuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • rocuronium

                dimenhydrinate increases toxicity of rocuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • sage

                dimenhydrinate and sage both increase sedation. Minor/Significance Unknown.

              • scopolamine

                dimenhydrinate increases toxicity of scopolamine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • Siberian ginseng

                Siberian ginseng increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

              • solifenacin

                dimenhydrinate increases toxicity of solifenacin by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • tiotropium

                dimenhydrinate increases toxicity of tiotropium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • tolterodine

                dimenhydrinate increases toxicity of tolterodine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • trospium chloride

                dimenhydrinate increases toxicity of trospium chloride by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • vecuronium

                dimenhydrinate increases toxicity of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

              • warfarin

                dimenhydrinate increases effects of warfarin by unknown mechanism. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Varies in incidence and severity with the individual drug; also individual patients vary in susceptibility

              Frequency Not Defined

              Paradoxical CNS stimulation (children and occasionally in adults)

              CNS depression

              Drowsiness

              Sedation ranging from mild drowsiness to deep sleep (most frequent)

              Dizziness

              Lassitude

              Disturbed coordination

              Muscular weakness

              Restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures is less common

              Epigastric distress

              Anorexia

              Nausea

              Vomiting

              Diarrhea

              Constipation

              Cholestasis, hepatitis, hepatic failure, hepatic function abnormality, jaundice is rare

              Eczema, pruritus, inflammation, papular rash, erythema on exposed skin may occur with topical formulation

              Tachycardia, palpitation ECG changes (eg, widened QRS)

              Arrhythmias (eg, extrasystole, heart block)

              Hypotension

              Hypertension

              Dizziness, sedation, and hypotension may occur in geriatric patients

              Dryness of mouth, nose, and throat

              Dysuria

              Urinary retention

              Impotence

              Vertigo

              Visual disturbances

              Blurred vision

              Diplopia; tinnitus

              Acute labyrinthitis

              Insomnia

              Tremors

              Nervousness

              Irritability

              Facial dyskinesia

              Tightness of the chest

              Thickening of bronchial secretions

              Wheezing

              Nasal stuffiness

              Sweating

              Chills

              Early menses

              Toxic psychosis

              Headache

              Faintness

              Paresthesia

              Agranulocytosis

              Hemolytic anemia

              Leukopenia

              Thrombocytopenia

              Pancytopenia

              Previous
              Next:

              Warnings

              Contraindications

              Documented hypersensitivity to dimenhydrinate or diphenhydramine

              Lower respiratory disease, eg, asthma (controversial)

              Preemies and neonates

              Nursing women

              Cautions

              May impair ability to drive or operate heavy machinery

              May mask early signs of ototoxicity if given concomitantly with ototoxic drugs (eg, aminoglycosides)

              Patients with seizures, angle-closure glaucoma, enlargement of prostate gland, asthma, emphysema, acute hepatic insufficiency

              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: B

              Lactation: Crosses into breast milk, discontinue drug or do not nurse

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Ethanolamine H1 antagonist containing diphenhydramine and 8-chloro-theophylline; pharmacological effects principally result from diphenhydramine moiety, has CNS depressant, anticholinergic, antiemetic, antihistamine, and local anesthetic effects

              Antiemetic action may result from inhibiting vestibular stimulation, and inhibiting acetylcholine

              Pharmacokinetics

              Half-Life: unknown, (half-life of diphenhydramine is about 3.5 hr)

              Duration: 3-6 hr

              Onset: 20-30 min (IM); 15-30 min (PO); almost immediately (IV)

              Bioavailability: Well absorbed

              Metabolism: Extensively metabolized in the liver, based on data for diphenhydramine

              Excretion: Principally in urine (as metabolites)

              Previous
              Next:

              Administration

              IV Compatibilities

              Solution: compatible with most common solvents

              Additive: amikacin, amobarbital (at 1 g amobarbital/500 mg dimenhydrinate), calcium gluconate, chloramphenicol sodium succinate, corticotropin, heparin, hydroxyzine, norepinephrine, penicillin G, pentobarbital, phenobarbital, KCl, prochlorperazine, vancomycin, vitamin B/C

              Syringe: atropine, codeine, diatrizoate meglumine, diatrizoate sodium, diphenhydramine, droperidol, fentanyl, heparin, hydromorphone, hyoscine, iothalamate meglumine, iothalamate sodium, meperidine, metoclopramide, morphine, pentazocine, perphenazine, ranitidine, scopolamine

              Y-site: acyclovir

              IV Incompatibilities

              Additive: aminophylline (at 1g/L aminophylline and 500 mg/L dimenhydrinate; may be compatible at lower conc), ammonium chloride(?), hydrocortisone (at 500 mg hydrocortisone and 500 mg dimenhydrinate; may be compatible at lower conc), thiopental

              Syringe: butorphanol, chlorpromazine, glycopyrrolate, hydroxyzine, iodipamide, midazolam, nalbuphine, papaveretum, pentobarbital, prochlorperazine, promazine, promethazine, thiopental

              IV Administration

              50 mg in 10 mL NS over 2 min

              Storage

              Do not use if cloudy or contains a precipitate

              Store at controlled room temp 15-30°C

              Protect from freezing

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              Motion Sickness Relief oral
              -
              50 mg tablet
              Motion Sickness Relief oral
              -
              50 mg tablet
              Driminate oral
              -
              50 mg tablet
              Driminate oral
              -
              50 mg tablet

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Select a drug:
              Patient Education
              dimenhydrinate oral

              DIMENHYDRINATE - ORAL

              (DYE-men-HYE-dri-nate)

              COMMON BRAND NAME(S): Dramamine

              USES: Dimenhydrinate is an antihistamine used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness.Do not use this medication in children younger than two years unless directed by the doctor.

              HOW TO USE: Follow all directions on the product package. If your doctor has prescribed this medication, take it as directed. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth with or without food. Measure liquid forms of this medication using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose. The chewable tablets should be chewed thoroughly before being swallowed.The dosage is based on your age, medical condition, and response to treatment. Do not increase your dose or take this medication more often than directed.To prevent motion sickness, take the first dose 30 to 60 minutes before starting activity such as travel.Tell your doctor if your condition does not improve or if it worsens.

              SIDE EFFECTS: Drowsiness, constipation, blurred vision, or dry mouth/nose/throat may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.To relieve dry mouth, suck (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water, or use a saliva substitute.If your doctor has directed you to use this medication, remember that he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: mental/mood changes (such as restlessness, confusion), fast/irregular heartbeat, shaking (tremor), difficulty urinating.Get medical help right away if you have any very serious side effects, including: seizures.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Before taking dimenhydrinate, tell your doctor or pharmacist if you are allergic to it; or to diphenhydramine; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: breathing problems (such as asthma, emphysema), high pressure in the eye (glaucoma), heart problems, high blood pressure, liver disease, seizures, stomach/intestine problems (such as ulcers, blockage), overactive thyroid (hyperthyroidism), difficulty urinating (for example, due to enlarged prostate).This drug may make you drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Liquid products or chewable tablets may contain sugar and/or aspartame. Caution is advised if you have diabetes, phenylketonuria (PKU), or any other condition that requires you to limit/avoid these substances in your diet. Ask your doctor or pharmacist about using this product safely.Children may be more sensitive to the side effects of this drug. This drug can often cause excitement in young children instead of drowsiness.Older adults may be more sensitive to the side effects of this drug, especially drowsiness, confusion, constipation, or trouble urinating. Drowsiness and confusion can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.This drug passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding.

              DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: antihistamines applied to the skin (such as diphenhydramine cream, ointment, spray).Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or other antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.This medication may interfere with certain laboratory tests (including allergy skin test), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe drowsiness, seizures, widened pupils. In children, mental/mood changes (such as restlessness, irritability, hallucinations) may occur before drowsiness.

              NOTES: Keep all regular medical and laboratory appointments.

              MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of your next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

              STORAGE: Store at room temperature away from moisture and light. Do not store in the bathroom. Do not freeze liquid forms of this medication. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

              Information last revised June 2020. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.